



ADDF Program-Related Investment Contracting Policy for For-Profit Entities

The Alzheimer's Drug Discovery Foundation (ADDF) mission is to accelerate discovery of a novel treatment for Alzheimer's disease and other related dementias. The ADDF seeks to fulfill its mission by providing funding for drug discovery and development projects. As a public charity, the ADDF funding must be used specifically for an approved scientific project that advances the ADDF's stated mission.

The ADDF's funding to for-profit entities is provided in the form of a program-related investment (PRI) which supports the mission of the ADDF. Under U.S. Treasury Department regulations, PRIs are structured to enable the ADDF to receive a "return on investment" which is returned to the ADDF to increase its capacity to support more research in furtherance of its charitable mission.

Terms of the PRIs may vary. Please contact Adam Liebling, Senior Grants Manager, at (212) 901-8005 or aliebling@alzdiscovery.org with questions regarding this policy or the application process.